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Background: Hypoxia-induced changes may allow tumor cells to survive under sustained
hypoxic microenvironments resulting in achievement of more aggressive phenotypes. The
purpose of this study is to determine the prognostic relevance of the expression of carbonic
anhydrase IX (CA IX), a hypoxia-related protein in surgically resected squamous cell carci-
noma of the tongue. We also relate CA IX to Ki-67 expression representing tumor cell prolifer-
ation to provide a prognostic model.
Methods: We analysed the expression of CA IX and Ki-67 with immunohistochemistry in 60
patients with squamous cell carcinoma of the tongue.
Results: The percentage of CA IX-positive tumor cells had a wide variation from 0.0 to
77.5%, and the Ki-67 expression was 1.50–75.1%. High CA IX and Ki-67 expression
(10.0% of tumor cells positively stained with CA IX and Ki-67) was associated with a poorer
overall survival (P, 0.05). High CA IX and Ki-67 expression showed shorter disease-free sur-
vival (DFS), although they are not statistically significant. To make a risk model based on the
expression of CA IX and Ki-67, we divided the patients into three groups: high risk (high CA
IX and Ki-67), low risk (low CA IX and Ki-67) and intermediate risk (either high CA IX or
Ki-67). Being in the high-risk group was found to be an independent prognostic factor for
overall survival and DFS in multivariate analysis (P, 0.05).
Conclusion: The expression of CA IX and Ki-67 may be useful for predicting prognosis in
squamous cell carcinoma of the tongue.
Key words: carbonic anhydrase IX – Ki-67 – hypoxia – squamous cell carcinoma – tongue
INTRODUCTION
Hypoxia is a common pathophysiological consequence of a
disturbed microcirculation in tumors as tumor cells outgrow
their blood supply (1). In the past, tumor hypoxia was
regarded as mainly associated with poor response to radio-
therapy or chemotherapy, because adequate blood supply is
generally required for their anti-cancer effects (2,3).
However, the relationship between tumor hypoxia and the
aggressive phenotype of tumors has also been suggested.
Thus, a variety of genetic changes within tumor cells may
occur under hypoxia. These changes may help tumor cells
survive under hypoxic microenvironment. Therefore, a clone
of tumor cells achieving these hypoxia-induced changes can
have more aggressive phenotype resulting in invasion and
metastasis (1,4). Thus, the hypoxia-induced changes may be
indirect indicators for more aggressive phenotype and worse
prognosis.
Hypoxia can stabilize and increase the hypoxia-inducible
factor-1a, which is a major transcription factor activating
.40 target genes including carbonic anhydrases (5).
Therefore, the products of these genes can be used to assess
tumor hypoxia in routine clinical biopsy samples such as
parafﬁn-embedded blocks. Carbonic anhydrase IX (CA IX)
is a transmembrane enzyme frequently overexpressed in a
variety of tumors, and associated with hypoxia and tumor
aggressiveness (6–8). CA IX catalyzes the reversible
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hydration of carbon dioxide to carbonic acid (9,10). This
leads to intracellular alkalosis and extracellular acidosis in
the tumor microenvironment, which allows tumors to survive
under hypoxic conditions (11,12). Furthermore, extracellular
acidosis facilitates the breakdown of the extracellular matrix
promoting local invasion and metastasis (13). Thus, the
expression of CA IX in tumor samples may stand for the
presence of hypoxia and tumors cells with more aggressive
phenotype due to hypoxia-induced cellular changes.
In the past, cells were thought to proliferate slowly or not
at all under hypoxic conditions. However, previous studies
have suggested the possibility of continuous cellular growth
in the hypoxic compartment of tumors (14,15). Although the
exact relationship remains unclear, the presence of cells pro-
liferating in the hypoxic compartment may represent more
aggressive clones selected by hypoxia. Therefore, pre-
treatment characterization of tumor hypoxia and proliferation
may be useful for predicting prognosis, and this approach
may help establish a treatment strategy. In this study, we eval-
uated a series of squamous cell carcinomas of the tongue with
the primary treatment of surgery to assess the prognostic
value of CA IX, which was known as a marker for tumor
hypoxia. We also analysed the Ki-67 expression representing
the fraction of cellular proliferation to prove its prognostic rel-
evance in patients surgically treated tongue squamous cell
carcinoma. Thus, we have determined their prognostic value
in univariate and multivariate analyses focussing on squamous
cell carcinomas developed from the tongue.
PATIENTS AND METHODS
PATIENTS AND TISSUES
Sixty patients with squamous cell carcinoma of the tongue at
the Korea University Medical Center were included in this
study from 1997 to 2004. All patients underwent primary
surgery as a frontline treatment. All of the patients were
staged at the time of surgery following the guidelines of the
American Joint Committee on Cancer Staging. Patients
received postoperative adjuvant radiation therapy in a multi-
disciplinary setting. Thus, 41 patients received radiation
therapy after surgery (68.3%) and 19 patients received
surgery alone (31.7%). Among formalin-ﬁxed, parafﬁn-
embedded archival tissue blocks of squamous cell carcinoma
of tongue, we selected the best section from each block
representing tumor areas after review of all hematoxylin
slides. The included samples were originated from complete
resection material. Follow-up data were obtained from
medical records. Survival times were measured from the
date of surgery. This study was approved by the Institutional
Review Board of Korea University Medical Center.
IMMUNOHISTOCHEMISTRY
Immunohistochemistry for CA IX and Ki-67 was performed
using consecutive 4 mm serial sections of formalin-ﬁxed,
parafﬁn-embedded tissues placed onto positively charged
glass slides using a single-staining procedure. Two observers
reviewed the immunostained slides, and disagreement
between the two observers was resolved by consensus. All of
the interpretations of the immunohistochemistry were
without knowledge of the patient clinical outcome.
CARBONIC ANHYDRASE IX (CA IX)
We used the anti-CA IX mouse monoclonal antibody clone
M75 (gift from Dr E.O.). Tissue sections were dewaxed and
rehydrated followed by antigen retrieval by incubation with
proteinase K (S3028, Dako, Copenhagen, Denmark) for
5 min. Staining was performed using an Envision kit
(K4007, Dako). After blocking with 10% human serum to
prevent non-speciﬁc binding for 30 min, the slides were
incubated with the primary antibody (10 mg/ml) for 1 h at
room temperature. After the incubation with labeled HRP of
Envision kit for 30 min, color was developed by 5 min incu-
bation in 3,30-diaminobenzidine (DAB) solution. A positive
control was used with human cervical squamous cell carci-
noma tissue that was previously established to be positive
for CA IX (16,17). Two batch controls were included in
each run to assess variability of immunohistochemistry.
After the slides were scanned at low magniﬁcation (40),
three areas (per case) of maximum CA IX expression were
selected as previously described (15). The degree of CA IX
staining on each selected ﬁeld was assessed at high magniﬁ-
cation (200) based on the semiquantitative scale of 0–3:
grade 0, no staining; grade 1, light staining; grade 2, moder-
ate staining; grade 3 intense staining. Grade 3 staining
means the equal intensity to positive control (cervical squa-
mous cell carcinoma). The percentage of tumor cells stained
for CA IX was measured at low magniﬁcation (40). The
mean value of the examined ﬁelds was designated as the
ﬁnal value for each case.
KI-67
For the detection of Ki-67, we performed immunostaining
with the anti-Ki-67 mouse monoclonal antibody (clone
MIB-1, DakoCytomation, CA, USA) based on the above-
mentioned procedure. When tumor cells showed intranuclear
DAB staining, they were considered positive for the Ki-67
antigen. After the slides were scanned at low magniﬁcation
(40), three areas (per case) of maximum Ki-67 expression
were selected. The cells with positively stained nuclei were
counted in there ﬁelds at high magniﬁcation (400). The
percentage of Ki-67 expression was quantiﬁed by determin-
ing the number of positive cells expressing nuclear Ki-67
among the total number of tumor cells per high power ﬁeld.
STATISTICAL ANALYSIS
The Fisher’s exact test was applied to assess the association
between categorical variables. Thus, the correlation of each
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marker expression with clinical and pathological character-
istics was tested in univariate analysis. The coefﬁcient of
correlation (r) between expressions of markers was calcu-
lated using the Spearman’s rank test. The period of overall
survival (OS) was measured from the date of surgery to the
date of death or the last follow-up visit. Disease-free survival
(DFS) was measured from the date of surgery to the date of
disease relapse or the date of the last follow-up visit. OS and
DFS curves were calculated using the Kaplan–Meier
method and compared by the log-rank test. The Cox pro-
portional hazards regression model was used for multivariate
analyses. All the statistical analyses were performed using a
statistical software package (SPSS, Version 10.0, Inc.,
Chicago, IL, USA). Statistical signiﬁcance was deﬁned as
p-values ,0.05. All p-values were two-sided.
RESULTS
CLINICAL AND PATHOLOGICAL PATIENT CHARACTERISTICS
The clinical and pathological characteristics of the patients
enrolled in this study are summarized in Table 1. The
median follow-up duration at the time of analysis was 29.51
months (range 4.10–117.13 months). The median age of the
patients at diagnosis was 54.9 years (range 20.0–79.4 years),
and the ratio of males to females was 2:1. Twenty-nine
patients had Stages I and II disease (48.4%), and 20 cases
developed from the tongue base. There were 30 patients with
relapse during follow-up; among them 22 deaths occurred;
19 were cancer-related deaths and 3 were not related to the
cancer: 1 acute myocardial infarction, 1 subarachnoid hemor-
rhage and 1 pneumonia. There were 30 patients alive without
evidence of disease relapse, and eight patients were alive
with disease.
CA IX AND KI-67 EXPRESSION
The immunostaining for CA IX expression showed a mem-
branous and/or cytoplasmic staining pattern. We designated
positive CA IX expression as those with membranous and/or
cytoplasmic staining with an intensity of grade 3 (Fig. 1A)
to exclude false positive cases such as non-speciﬁc or
vaguely immunostained cases. The distribution of positive
CA IX expression was focal and predominantly found
around necrotic areas. The percentage of CA IX-positive
tumor cells had a wide variation from 0.0 to 77.5%. The
intensity of CA IX immunostaining was signiﬁcantly corre-
lated with the percentage of CA IX positive tumor cells
(P, 0.05). Positive Ki-67 expression was deﬁned by nuclear
staining for Ki-67 antigen, and the range of percentage of
Ki-67 expression was 1.50–75.1% (Fig. 1B).
To assess the inter-relationships between CA IX and
Ki-67 expression, the percentage of CA IX-positive tumor
cells was compared with Ki-67 expression using the
Spearman’s rank test. CA IX expression showed a weak cor-
relation with Ki-67 expression (r ¼ 0.373, P ¼ 0.0008,
Table 1. Characteristics of patients
Characteristics No. of patients
(%)
Gender
Male 40 (66.7)
Female 20 (33.3)
Age
Median, range (54.9, 20.0–79.4)
,60 43 (71.7)
60 17 (28.3)
Primary site of involvement
Anterior 6 (10.0)
Lateral 34 (56.7)
Base 20 (33.3)
Degree of differentiation
Well differentiated 35 (58.3)
Moderately/poorly differentiated 25 (41.7)
T stage
T1/T2 18/28 (30.0/46.6)
T3/T4 7/7 (11.7/11.7)
N stage
N0 33 (55.0)
N1 9 (15.0)
N2 18 (30.0)
Stage
I/II 13/16 (21.7/26.7)
III/IV 10/21 (16.6/35.0)
Treatment
Surgery followed by radiotherapy 41 (68.3)
Surgery alone 19 (31.7)
Smoking
Yes 30 (50.0)
No 30 (50.0)
Resection margin
Negative 50 (83.3)
Positive 10 (16.7)
Relapse
Yes 30 (50.0)
No 30 (50.0)
Health status
Alive without disease 30 (50.0)
Alive with disease 8 (13.3)
Cancer-related death 19 (31.7)
Non-cancer-related death 3 (5.0)
T, tumor; N, lymph node.
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Fig. 2). When we compared the CA IX expression with
Ki-67 expression in the same ﬁeld, tumor areas positive for
CA IX also showed the presence of tumor cells positively
stained for Ki-67 (Fig. 2). These ﬁndings suggest that the
proliferating tumor cells may exist in the tumor areas with
high CA IX expression representing hypoxic microenviron-
ment. This is consistent with the possibility of continuous
cellular growth in the hypoxic compartment of tumors.
ASSOCIATION WITH CLINICAL AND PATHOLOGICAL
CHARACTERISTICS
We used the percentage of tumor cells positively stained
with CA IX and Ki-67 to designate high and low expression
instead of the staining intensity. Thus, we designated 10.0%
as a cut-off value for high CA IX expression because 22
cases with ,10.0% showed the range of 0.0–2.5%. For
Ki-67 expression, 10.0% was used as a cut-off value to
dichotomize patients into high and low expression group
because it is a median value.
High CA IX expression was more frequently observed in
moderately or poorly differentiated tumors compared with
the well-differentiated tumors (P ¼ 0.007), whereas Ki-67
expression did not correlate with the degree of differentiation.
When we compared their expression based on the site of
involvement, tongue base showed high CA IX and Ki-67
expression than other sites of involvement such as lateral or
anterior tongue (P, 0.05). Nodal involvement was
Figure 1. Representative staining of carbonic anhydrase IX and Ki-67 (magniﬁcation 200). (A) CA IX expression, brown colored cytoplasmic and membra-
nous staining. (B) Ki-67 expression, brown colored nuclear staining. CA, carbonic anhydrase.
Figure 2. Inter-relationship of CA IX and Ki-67 expression. (A) The percentage of CA IX-positive cells showed a weak correlation with Ki-67 expression
(r ¼ 0.373, P ¼ 0.0008). (B) Immunohistochemistry was performed (magniﬁcation 200), and CA IX expression was compared with Ki-67 expression.
Jpn J Clin Oncol 2007;37(11) 815
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correlated with Ki-67 expression, and however, stage was not
associated with CA IX or Ki-67 expression. Smoking status
was signiﬁcantly associated with CA IX expression (P ¼
0.003). Patients treated with adjuvant radiotherapy had
higher CA IX and Ki-67 expression than patients treated with
surgery alone (Table 2). Because we have decided to perform
postoperative radiotherapy for patients with high probability
of relapse or unfavorable histological characteristics, these
ﬁndings suggest that CA IX and Ki-67 expression might be
related with an aggressive tumor phenotype.
RELATIONSHIP WITH PROGNOSIS
Among the 30 cases with relapse, 27 were loco-regional and
3 were at distant sites: lung and bone metastasis. Tumor
relapse was not signiﬁcantly related with the expression of
CA IX and Ki-67, although 22 cases with relapse showed
high CA IX expression (Table 2). When the overall survival
was analysed in the univariate analysis, high CA IX and
Ki-67 expression was signiﬁcantly associated with a poorer
overall survival as illustrated by Kaplan–Meier curves
(Fig. 3A). The DFS (P. 0.05, Fig. 2B) was not signiﬁcantly
different based on these markers’ expression. However, high
CA IX and Ki-67 expression showed shorter DFS than low
CA IX and Ki-67, although they are not statistically
signiﬁcant (Fig. 3B).
Thus, we made an expression proﬁle with CA IX
and Ki-67 expression status for risk-stratiﬁcation model. We
divided the patients into three groups depending on
the expression of CA IX and Ki-67: the group with a high
expression of CA IX and Ki-67 (designated as high risk), the
group with a high expression of CA IX or Ki-67 (designated
as intermediate risk) and the group with low expression of
CA IX and Ki-67 (low risk). When we analysed DFS and
overall survival based on these risk groups, there was a sig-
niﬁcant association with poorer overall and DFS (Fig. 4A
and B). This risk-stratiﬁcation model was also signiﬁcantly
associated with the site of involvement, the degree of differ-
entiation and relapse rate (Table 3).
To examine the independent prognostic signiﬁcance of
this expression proﬁle with CA IX and Ki-67, multivariate
analysis was performed with clinical pathological charac-
teristics including age, stage, location of primary site, pre-
sence of tumor cells in the resection margin, degree of
differentiation and treatment modality. The risk model
based on the expression proﬁle of CA IX and Ki-67 was
an independent prognostic factor for overall survival and
DSF (p ¼ 0.005, 0.007, respectively, Table 4).
DISCUSSION
Squamous cell carcinoma of the oral cavity is estimated to
be the twelfth most common cancer (18), among which the
tongue is one of the most frequent sites. In most cases of
squamous cell carcinoma of the tongue, the primary treat-
ment is surgical resection alone or combined with
postoperative radiotherapy (19). Despite advances in surgical
techniques, the overall prognosis remains poor and
loco-regional relapse accounts for most treatment failures
(19). Our results showed 27 loco-regional relapsed cases
among 30 cases with relapse emphasizing the need for better
local control of this disease. Although the resection margin
is one of the most important factors closely related to
relapse, our study demonstrated a limited number of cases
with a positive resection margin; when a positive margin
was present it was not signiﬁcantly associated with relapse
or survival (P . 0.05, data not shown); only 5 cases had a
Table 2. Correlations of CA IX and Ki-67 with clinical and pathological
characteristics
Characteristics CA IX Ki-67
,10% 10% ,10% 10%
Gender
Male 12 28 17 23
Female 10 10 0.161 12 8 0.275
Age
,60 16 27 20 23
60 6 11 1.000 9 8 0.777
Location
Anterior 1 5 2 4
Lateral 17 17 22 12
Base 4 16 0.049 5 15 0.014
Differentiation
Well 18 17 20 15
Moderately/
poorly
4 21 0.007 9 16 0.124
T stage
T1/T2 17 29 23 23
T3/T4 5 9 1.000 6 8 0.763
N stage
N0 13 20 21 12
N1–2 9 18 0.789 8 19 0.011
Stage
I/II 12 17 17 12
III/IV 10 21 0.593 12 19 0.196
Surgery þ
radiotherapy
12 29 16 25
Surgery alone 10 9 0.094 13 6 0.052
Smoking
Non-smoker 17 13 18 12
Smoker 5 25 0.003 11 19 0.120
Relapse
Yes 8 22 12 18
No 14 16 0.180 17 13 0.301
CA, carbonic anhydrase.
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Figure 3. Overall and disease-free survival analysis. (A) High CA IX and Ki-67 expression (the percentage of positively stained tumor cells 10.0%) was sig-
niﬁcantly associated with poorer overall survival in the univariate analysis as illustrated by Kaplan–Meier curves. (B) Disease-free survival was not associated
with high CA IX and Ki-67 expression, although they showed a trend towards better disease-free survival.
Figure 4. Survival analysis based on the proﬁle of CA IX and Ki-67. The group with a high expression of CA IX and Ki-67: high-risk group, the group with
a high expression of CA IX or Ki-67: intermediate-risk group and the group with low expression of CA IX and Ki-67: low-risk group. The high-risk group
shows a signiﬁcant association with poorer overall survival (A) and disease-free survival (B).
Jpn J Clin Oncol 2007;37(11) 817
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positive resection margin among 30 relapses. The extent of
the primary tumor and the state of the regional lymph nodes
are known to correlate with prognosis (19,20). However, a
substantial number of patients with early stage disease have
relapse and a poor prognosis. In our study, the stage includ-
ing T stage and N stage correlated with overall survival.
However, there were 12 relapsed cases among 29 patients
with Stage I/II (41.4%). Thus, there is a need to identify
additional prognostic parameters that can complement the
current TNM staging system.
Our study showed a signiﬁcant relationship between the
expression of CA IX and Ki-67 and overall survival.
Although the results were not statistically signiﬁcant
(P. 0.05), the group with high CA IX and Ki-67 expression
had a poorer DSF. These ﬁndings are consistent with previous
reports on the prognostic value of CA IX for oral squamous
cell carcinoma (8,21). CA IX has been extensively studied as
a prognostic factor in a variety of tumors especially in squa-
mous cell carcinoma. This is because squamous cell carci-
noma is frequently accompanied by necrosis and CA IX is
expressed predominantly around necrosis. This perinecrotic
expression reﬂects the association of CA IX with hypoxia
(15,22). In this study, we also observed dominant expression
of CA IX around necrotic areas. Co-localization of an exogen-
ous marker of hypoxia, pimonidazole, with CA IX supports
the association of CA IX with hypoxia in the tumor microen-
vironment (6,23). However, the relationship of CA IX with
hypoxia and prognosis is debated because some reports have
not shown an association (17,24). But our results showing the
correlation of CA IX expression with prognosis may become
indirect evidence that hypoxia is a poor prognostic sign.
In this study, a weak correlation was observed between CA
IX and KI-67 expression. Although their correlation was not
strong, these ﬁndings suggest at least the presence of prolifer-
ating tumor cells in the tumor areas with high CA IX
expression representing hypoxic microenvironment. These are
consistent with prior reports about the correlation of cellular
proliferation with hypoxic microenvironment (15,25,26). The
proliferating tumor cell clones under hypoxic conditions may
represent tumor cells developing a more aggressive phenotype
(15,27), and the co-expression of hypoxia markers and Ki-67
may represent tumor aggressiveness. Thus, when we combine
the expression of CA IX and Ki-67, the group of patients with
CA IX and Ki-67 designated as a high-risk group had a
poorer overall survival and DSF, although each factor failed
to show a correlation with DSF.
Table 3. Correlations of risk stratiﬁcation model with clinical and
pathological characteristics
Characteristics Risk
Low Intermediate High P value
Gender
Male 7 15 18 0.206
Female 7 8 5
Age
,60 11 14 18 0.343
60 3 9 5
Location
Anterior 1 1 4 0.013
Lateral 12 15 7
Base 1 7 12
Differentiation
Well 12 14 9 0.020
Moderately/poorly 2 9 14
T stage
T1/T2 12 16 18 0.516
T3/T4 2 7 5
N stage
N0 11 12 10 0.108
N1–2 3 11 13
Stage
I/II 10 9 10 0.136
III/IV 4 14 13
Surgery þ radiotherapy 6 16 19
Surgery alone 8 7 4 0.041
Smoking
Non-smoker 12 11 7
Smoker 2 12 16 0.005
Relapse
Yes 3 9 13
No 11 14 10 0.049
Table 4. Cox proportional hazards regression model analysis of disease free
survival and overall survival
Variables Overall survival Disease-free survival
Coefﬁcient SE P value Coefﬁcient SE P value
Sex 0.561 0.586 0.324 0.703 0.457 0.440
Age 60 3.014 0.560 0.049 2.236 0.435 0.064
Location: base 1.815 0.419 0.155 1.678 0.430 0.229
Moderately/
poorly
differentiated
0.383 0.562 0.088 0.730 0.454 0.487
Positive
resection margin
1.333 0.591 0.627 0.876 0.573 0.818
Surgery þ
radiotherapy
0.847 0.910 0.855 0.258 0.594 0.023
Stage III/IV 3.360 0.653 0.063 2.457 0.520 0.084
CAIX/Ki-67
risk: high
4.040 0.494 0.005 2.386 0.324 0.007
SE, standard error of the coefﬁcient.
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Our study population was conﬁned to squamous cell carci-
noma of the tongue, because most prior studies on the prog-
nostic value of CA IX and Ki-67 have been in head and neck
squamous cell carcinoma including various sites of the head
and neck such as larynx, pharynx, nasal cavity and ﬂoor of
the mouth (8,21). This is the ﬁrst study on the prognostic
value of CA IX and Ki-67 in patients with squamous cell car-
cinoma of tongue. Although the staging system of the
American Joint Committee on Cancer Staging is the accepted
predictor of prognosis, the survival data for each stage shows
heterogeneous populations; patients with the same stage
disease vary, and some have a poorer prognosis than others
do. Therefore, identifying patients at high risk for a poor prog-
nosis would allow for the development of treatment strategies.
Considering the prognostic signiﬁcance of the proﬁle combin-
ing CA IX and Ki-67 expression demonstrated in our study,
these factors might be useful for selecting patients who
require additional treatment before or after primary treatment.
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